Daré Bioscience has received a consensus rating of Buy. The company’s average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Similarly Is DARE stock a good buy? According to 11 analysts, the average rating for DARE stock is « Buy. » The 12-month stock price forecast is 7.34, which is an increase of 433.82% from the latest price.
What is Daré Bioscience FDA approval? Daré’s New Drug Application (NDA) for XACIATO (clindamycin phosphate) vaginal gel (formerly known as DARE-BV1) was approved by the FDA on December 7, 2021 .
Additionally, What does Daré Bioscience do?
Dare Bioscience, Inc. operates as a healthcare company. The Company offers women’s reproductive health devices, therapeutics, and diagnostics. Dare Bioscience provides contraception, vaginal health, pain, and fertility products.
Will Dare Bioscience stock go up?
Stock Price Forecast
The 5 analysts offering 12-month price forecasts for Dare Bioscience Inc have a median target of 6.00, with a high estimate of 17.00 and a low estimate of 3.00. The median estimate represents a +282.17% increase from the last price of 1.57.
What is the stock of DARE Pharma? (DARE) Stock Price, News, Quote & History – Yahoo Finance.
…
Performance Outlook.
| Previous Close | 1.4900 |
|---|---|
| 52 Week Range | 1.2000 – 2.5100 |
| Volume | 6,361,573 |
| Avg. Volume | 2,143,816 |
What rating is dare Bioscience? The consensus rating score for Daré Bioscience is 3.00 while the average consensus rating score for medical companies is 2.73.
How much is target DARE? Stock Price Targets
| High | $17.00 |
|---|---|
| Median | $6.00 |
| Low | $3.00 |
| Average | $7.20 |
| Current Price | $1.4100 |
When was DARE Stock FDA approved?
Development Timeline for Xaciato
| Date | Article |
|---|---|
| Dec 7, 2021 | Approval FDA Approves Xaciato (clindamycin phosphate) Vaginal Gel as a Treatment for Bacterial Vaginosis |
| Aug 9, 2021 | Daré Bioscience Announces FDA Acceptance and Priority Review of New Drug Application for DARE-BV1 for the Treatment of Bacterial Vaginosis |
• 8 déc. 2021
Who is the CEO of DARE Bioscience? Sabrina Martucci Johnson. Ms. Johnson founded Daré Bioscience Operations in 2015 and has served as President, CEO and a member of the Board of Directors since its inception and following its business combination with Cerulean Pharma in July 2017, when the Company was renamed Daré Bioscience.
Is DARE Stock FDA approved?
On December 7, 2021, Daré announced that the U.S. Food and Drug Administration (FDA) approved XACIATO [zah-she-AH-toe] (clindamycin phosphate vaginal gel, 2%) (formerly known as DARE-BV1) for the treatment of bacterial vaginosis in females 12 years of age and older.
Is DARE Stock News approved by the FDA? Dare Bioscience (NASDAQ:DARE) recently rallied 30.0% on the news of FDA approval of XACIATO for bacterial vaginosis in women on Dec. 7, 2021. Since the FDA approval DARE stock price has declined for no fundamental reason other than the stock market weakness.
Can I dare Bioscience bacterial vaginosis?
DARE-BV1 is an investigational thermosetting bioadhesive hydrogel containing clindamycin phosphate 2% designed as a one-time vaginally-administered treatment for bacterial vaginosis.
What is a Pdufa from FDA?
The Prescription Drug User Fee Act (PDUFA) was created by Congress in 1992 and authorizes FDA to collect fees from companies that produce certain human drug and biological products.
What is DARE Bioscience press release? Press Releases
- Daré Bioscience to Host Full-year 2021 Financial Results and Company Update Conference Call and Webcast on March 31, 2022. 03-24-2022.
- Daré Bioscience to Present at the Maxim 2022 Virtual Growth Conference. 03-22-2022.
- Daré Bioscience to Participate in Upcoming Conferences. 03-02-2022.
What is the new drug DARE? DARE-BV1, a gel that treats bacterial vaginosis, was granted FDA approval on its Prescription Drug User Fee Act (PDUFA) date today. DARE-BV1 (clindamycin phosphate) was approved today by the US Food and Drug Administration (FDA) to treat bacterial vaginosis.
What is Xaciato?
XACIATO is a lincosamide antibacterial indicated for the. treatment of bacterial vaginosis in female patients 12 years of. age and older. (
How much does an IND cost? FY 2014 – FY 2017
| Submission Type | FY 14 | FY 15 |
|---|---|---|
| Drug Applications | ||
| IND | $459.0 | $550.3 |
| NDA Clinical Data – NME | $5,646.4 | $5,250.5 |
| NDA with Clinical Data – Non-NME | $1,845.2 | $1,356.2 |
• 13 août 2018
What is the difference between BLA and NDA?
Whereas a new drug application (NDA) is used for drugs subject to the drug approval provisions of the FDC Act, a biologics license application (BLA) is required for biological products subject to licensure under the PHS Act. FDA form 356h is used for both NDA and BLA submissions.
How long does BLA approval take? Review Timeline
As per the Prescription Drug User Fee Act (PDUFA), the FDA agreed to review the majority of BLAs within 10 months of 60 day filing and for the priority submissions it has been cut down to 6 months of 60 day filing date.
What is the next dare bioscience event?
Clinical and Scientific Events
- 09-08-2021 to 09-10-2021. 13th European Congress on Menopause and Andropause. …
- 07-25-2021 to 07-29-2021. 2021 Controlled Release Society Virtual Annual Meeting. …
- 03-09-2020. …
- 10-07-2019 to 10-08-2019. …
- 08-08-2019 to 08-10-2019. …
- 07-22-2019 to 07-24-2019.
What is Pdufa action date? In United States pharmaceutical regulatory practice, the PDUFA date is the colloquial name for the date by which the Food and Drug Administration must respond to a New Drug Application or a Biologics License Application.
What happens on Pdufa date? In United States pharmaceutical regulatory practice, the PDUFA date is the colloquial name for the date by which the Food and Drug Administration must respond to a New Drug Application or a Biologics License Application.